Craig Fraser Biography and Net Worth

Craig was appointed Windtree’s President and Chief Executive Officer in February 2016 in addition to joining as a member of the Board of Directors.

Craig brings more than 29 years of experience as a leader in product development and commercial operations and in building biopharmaceutical and device businesses for both startups and larger companies. Prior to joining Windtree, Craig held executive positions at several biopharmaceutical companies, including as Chief Operating Officer at Novelion (AEGR) Therapeutics, Vice President of Global Disease Areas at Pfizer, Vice President and Global Business Manager at Wyeth and Vice President of Sales & Marketing and Commercial Operations at Johnson & Johnson / Centocor. Craig is a veteran of both the U.S. Marine Corps and the U.S. Army.

What is Craig Fraser's net worth?: The estimated net worth of Craig Fraser is at least $4,319.86 as of October 8th, 2024. Mr. Fraser owns 8,638 shares of Windtree Therapeutics stock worth more than $4,320 as of November 21st. This net worth approximation does not reflect any other investments that Mr. Fraser may own. Additionally, Mr. Fraser receives an annual salary of $567,200.00 as CEO at Windtree Therapeutics. Learn More about Craig Fraser's net worth.
How old is Craig Fraser?: Mr. Fraser is currently 59 years old. There are 4 older executives and no younger executives at Windtree Therapeutics. Learn More on Craig Fraser's age.
What is Craig Fraser's salary?: As the CEO of Windtree Therapeutics, Inc., Mr. Fraser earns $567,200.00 per year. Learn More on Craig Fraser's salary.
How do I contact Craig Fraser?: The corporate mailing address for Mr. Fraser and other Windtree Therapeutics executives is 2600 KELLY ROAD SUITE 100, WARRINGTON PA, 18976. Windtree Therapeutics can also be reached via phone at (215) 488-9300 and via email at [email protected]. Learn More on Craig Fraser's contact information.
Has Craig Fraser been buying or selling shares of Windtree Therapeutics?: In the last ninety days, Craig Fraser has bought $4,942.21 in Windtree Therapeutics stock. Most recently, on Tuesday, October 8th, Craig Fraser bought 5,431 shares of Windtree Therapeutics stock. The stock was acquired at an average cost of $0.91 per share, with a total value of $4,942.21. Following the completion of the transaction, the chief executive officer now directly owns 8,638 shares of the company's stock, valued at $7,860.58. Learn More on Craig Fraser's trading history.
Who are Windtree Therapeutics' active insiders?: Windtree Therapeutics' insider roster includes Craig Fraser (CEO), and James Huang (Director). Learn More on Windtree Therapeutics' active insiders.
Are insiders buying or selling shares of Windtree Therapeutics?: In the last year, Windtree Therapeutics insiders bought shares 1 times. They purchased a total of 5,431 shares worth more than $4,942.21. The most recent insider tranaction occured on October, 8th when CEO Craig Fraser bought 5,431 shares worth more than $4,942.21. Insiders at Windtree Therapeutics own 0.9% of the company. Learn More about insider trades at Windtree Therapeutics.
Information on this page was last updated on 10/8/2024.

Craig Fraser Insider Trading History at Windtree Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/8/2024	Buy	5,431	$0.91	$4,942.21	8,638
9/26/2023	Buy	138	$16.20	$2,235.60	3,076
4/25/2023	Buy	73	$34.02	$2,483.46	306
7/26/2022	Buy	1	$666.00	$666.00	124
6/29/2022	Buy	3	$756.00	$2,268.00	120
3/15/2022	Buy	1	$1,764.00	$1,764.00
11/18/2021	Buy	0	$2,898.00	$0.00
10/22/2021	Buy	1	$3,420.00	$3,420.00
10/19/2021	Buy	1	$3,438.00	$3,438.00
4/5/2021	Buy	0	$4,644.00	$0.00	15
3/31/2021	Buy	0	$4,176.00	$0.00	14
10/28/2020	Buy	0	$11,808.00	$0.00	13
10/9/2020	Buy	0	$10,494.00	$0.00	13
10/7/2020	Buy	0	$9,306.00	$0.00	13
10/28/2016	Buy	4	$3,690.00	$14,760.00	4

Craig Fraser Buying and Selling Activity at Windtree Therapeutics

Windtree Therapeutics Company Overview

Windtree Therapeutics, Inc., a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company's lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock. It also develops AEROSURF, an aerosolized KL4 surfactant that is in Phase 2b clinical trial to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant, which is in Phase 2a clinical trial for the treatment of lung injury resulting from COVID-19; Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activator, which is in preclinical trial for the treatment of chronic and acute heart failure. In addition, it is developing aPKCi Inhibitor for the treatment of cutaneous malignancies and solid tumors that is in preclinical trials. Windtree Therapeutics, Inc. has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sale of a portfolio of potential KL4 surfactant products; license, development and commercialization agreement with Lee's Pharmaceutical (HK) Ltd. and Zhaoke Pharmaceutical (Hefei) Co. Ltd.; license agreement with Philip Morris USA, Inc. and Johnson & Johnson; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. The company was founded in 1992 and is headquartered in Warrington, Pennsylvania.

Today's Range

Now: $0.51

$0.49

$0.52

50 Day Range

MA: $1.38

$0.47

$3.43

2 Week Range

Now: $0.51

$0.45

$22.36

Volume

227,768 shs

Average Volume

759,745 shs

Market Capitalization

$300,487.00

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.64

📉 Warning: Market Crash Predicted - Secure Your Savings

From Behind the Markets | Ad

The last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.

Take these 4 steps to protect your retirement here >>>

Craig Fraser Biography and Net Worth

What is Craig Fraser's net worth?

How old is Craig Fraser?

What is Craig Fraser's salary?

How do I contact Craig Fraser?

Has Craig Fraser been buying or selling shares of Windtree Therapeutics?

Who are Windtree Therapeutics' active insiders?

Are insiders buying or selling shares of Windtree Therapeutics?